Prevalence of HIV/AIDS among Iranian Prisoners: A Review Article

Document Type : Review Article(s)


1 Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 PhD Student, Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

3 PhD Student, Social Determinants of Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran

4 Assistant Professor, Department of Biostatistic and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran

5 Department of Health Education and Promotion, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran

6 Professor, Health Policy Research Center AND Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran


Background: Worldwide, prisoners are more at risk of being infected by human immunodeficiency virus (HIV) as well as hepatitis C and B in comparison with other risk groups. The combination of acquired immune deficiency syndrome (AIDS), addiction and prison are factors that threaten the health of our society. Influence of risky behaviors is so common on transmission of AIDS into prisoners’ bodies. This study used available information and reports to investigate the prevalence of HIV in Iranian prisons.Methods: The following review of documents available in national and foreign databases, a total of 26 studies were investigated and required information was extracted from both the full papers and abstracts.Findings: The selected studies differed methodologically in their sampling method and data collection tools. Within the 26 studies analyzed, there was a combined study cohort of 39707 people in whom HIV prevalence varied between 0% and 24.40%.Conclusion: In this study, HIV prevalence ranged widely among the prisoners, and in most of these studies, the rate in Iran was higher than that of other countries. The prevalence of disease was highest among intravenous drug users. Unless proper preventive and control plans among risk groups such as prisoners are not implemented in a timely and suitable manner, the risk of infection in the broader society will increase.


  1. Dolan K, Kite B, Black E, Aceijas C, Stimson GV. HIV in prison in low-income and middle-income countries. Lancet Infect Dis 2007; 7(1): 32-41.
  2. Shahbazi M, Farnia M, Moradi G, Ebrahimi B. The trend of HIV/AIDS prevalence among IDU's in Iranian prisoners (1376-1386). Retrovirology 2010; 7(Suppl 1): P101.
  3. Gaughwin M, Douglas RM, Wodak AD. Behind bars-risk behaviours for hiv transmission in prisons, a review [Online]. [cited 1991]; Available from: URL:
  4. Epperson MW, Khan MR, El-Bassel N, Wu E, Gilbert L. A longitudinal study of incarceration and HIV risk among methadone maintained men and their primary female partners. AIDS Behav 2011; 15(2): 347-55.
  5. Hellard ME, Aitken CK. HIV in prison: What are the risks and what can be done? Sex Health 2004; 1(2): 107-13.
  6. Wohl DA, Rosen D, Kaplan AH. HIV and incarceration: dual epidemics. AIDS Read 2006; 16(5): 247-60.
  7. Martin V, Cayla JA, Moris ML, Alonso LE, Perez R. Predictive factors of HIV-infection in injecting drug users upon incarceration. Eur J Epidemiol 1998; 14(4): 327-31.
  8. Harding TW. AIDS in prison. Lancet 1987; 2(8570): 1260-3.
  9. Tajbakhsh E, Yaghubi R. Serologic evaluation of HIV contamination in Shahrekord prisoners through ELISA and Western blot. Sci J Iran Blood Transfus Organ 2008; 4(5): 365-8. [In Persian].
  10. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: A review. Clin Infect Dis 2002; 35(3): 305-12.
  11. Farnia M, Ebrahimi B, Shams A, Zamani S. Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran. Int J Drug Policy 2010; 21(5): 422-4.
  12. Zamani S, Farnia M, Torknejad A, Alaei BA, Gholizadeh M, Kasraee F, et al. Patterns of drug use and HIV-related risk behaviors among incarcerated people in a prison in Iran. J Urban Health 2010; 87(4): 603-16.
  13. Seal DW. HIV-related issues and concerns for imprisoned persons throughout the world. Curr Opin Psychiatry 2005; 18(5): 530-5.
  14. Jahani MR, Kheirandish P, Hosseini M, Shirzad H, Seyedalinaghi SA, Karami N, et al. HIV seroconversion among injection drug users in detention, Tehran, Iran. AIDS 2009; 23(4): 538-40.
  15. Kheirandish P, Seyedalinaghi SA, Hosseini M, Jahani MR, Shirzad H, Foroughi M, et al. Prevalence and correlates of HIV infection among male injection drug users in detention in Tehran, Iran. J Acquir Immune Defic Syndr 2010; 53(2): 273-5.
  16. Hosseini M, SeyedAlinaghi S, Kheirandish P, Esmaeli JG, Shirzad H, Karami N, et al. Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran. Arch Iran Med 2010; 13(4): 318-23.
  17. Azarkar Z, Sharifzadeh G. Evaluation of the prevalence of hepatitis B, hepatitis C, and HIV in inmates with drug-related convictions in Birjand, Iran in 2008. Hepat Mon 2010; 10(1): 26-30.
  18. Kazerooni Afsar P, Amini Lari M, Joolaei H, Parsa N. Knowledge and attitude of male intravenous drug users on hiv/aids associated high risk behaviors in Shiraz Pir-Banon Jail, Fars Province, Southern Iran. Iran Red Crescent Med J 2010; 12(3): 334-6. [In Persian].
  19. Mir-Nasseri MM, Mohammadkhani A, Tavakkoli H, Ansari E, Poustchi H. Incarceration is a major risk factor for blood-borne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users. Hepat Mon 2011; 11(1): 19-22.
  20. Rahbar AR, Rooholamini S, Khoshnood K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. Int J Drug Policy 2004; 15(2): 151-5.
  21. Farhoudi B, Montevalian A, Motamedi M, Khameneh MM, Mohraz M, Rassolinejad M, et al. Human immunodeficiency virus and HIV-associated tuberculosis infection and their risk factors in injecting drug users in prison in Iran. Tehran, Iran: Ministry of Health and Medical Education; 2003. [In Persian].
  22. Akala FA, Semini I. Characterizing the HIV/AIDS Epidemic in the Middle East and North Africa: Time for Strategic Action. Washington, DC: World Bank Publications; 2010.
  23. Khodabakhshi B, Abbassi A, Fadaee F, Rabiee M. Prevalence and Risk Factors of HIV, Hepatitis B Virus and Hepatitis C Virus Infections in Drug Addicts among Gorgan Prisoners. J Med Sci 2007; 7(252): 254.
  24. Khani M, Vakili MM. Prevalence and risk factors of HIV, hepatitis b virus and hepatitis c virus infections in drug addicts among Zanjan prisoners. Archives of Iranian Medicine 2003; 6(1): 1-4.
  25. Ilami O, Sarkari B, Khosravani A, Tori MA, Hosseini Z. HIV seroprevalence among high-risk groups in Kohgiloyeh and Boyerahmad Province, Southwest of Iran, a behavioral surveillance survey. AIDS Behav 2012; 16(1): 86-90.
  26. Pourahmad M, Javady A, Karimi I, Ataei B, Kassaeian N. Seroprevalence of and risk factors associated with hepatitis B, hepatitis C, and human immunodeficiency virus among prisoners in Iran. Infect Dis Clin Pract 2007; 15(6): 368-72.
  27. Davoodian P, Dadvand H, Mahoori K, Amoozandeh A, Salavati A. Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002. Braz J Infect Dis 2009; 13(5): 356-8.
  28. Haghshenas MR, Mirmobini SM, Babamahmodi F. Prevalence of TB and HIV in prison in the city of Sari 1997-1998. J Mazandaran Univ Med Sci 2000; 9(26): 6-7. [In Persian].
  29. Center for Disease Control, Ministry of Health. Boibehavioural survey on HIV/AIDS among Khoozestan prisoners; 2008. [Unpublished]. [In Persian].
  30. Center for Disease Control, Ministry of Health. Study of the prevalence of Neisseria Gonorrhoeae, Clamidia Trachomatis, Syphilis and HIV in Kerman prisoners; 2008. [Unpublished]. [In Persian].
  31. Center for Disease Control, Ministry of Health. Boibehavioural survey on HIV/AIDS among Kermanshah prisoners; 2008. [Unpublished]. [In Persian].
  32. Khamisipoor G, Tahmasebi R. Viral infection of HBV, HCV, HIV and syphilis among high-risk groups, Bushehr. Iran South Med J 1999; 3(1): 53-9.
  33. Nokhodian Z, Yazdani MR, Yaran M, Shoaei P, Mirian M, Ataei B, et al. Prevalence and Risk Factors of HIV, Syphilis, Hepatitis B and C Among Female Prisoners in Isfahan, Iran. Hepat Mon 2012; 12(7): 442-7.
  34. Moosazadeh M, Amiresmaili M, Parsaei M, Ahmadi M, Jalahi H. Prevalence of tuberculosis among the prisoners of Mazandaran. J Rafsanjan Univ Med Sci 2011; 10(4): 309-16. [In Persian].
  35. Haghdoost AA, Mirzazadeh A, Shokoohi M, Sedaghat A, Gouya MM. HIV trend among Iranian prisoners in 1990s and 2000s; analysis of aggregated data from HIV sentinel sero-surveys. Harm Reduct J 2013; 10: 32.
  36. Navadeh S, Mirzazadeh A, Gouya MM, Farnia M, Alasvand R, Haghdoost AA. HIV prevalence and related risk behaviours among prisoners in Iran: Results of the national biobehavioural survey, 2009. Sex Transm Infect 2013; 89(Suppl 3): iii33-iii36.
  37. Ghanbarzadeh N, Nadjafi-Semnani M. A Study of HIV and other sexually transmitted infections among female prisoners in Birjand. J Birjand Univ Med Sci 2006; 13(3): 9-15. [In Persian].
  38. McDonald AM, Ryan JW, Brown PR, Manners CJ, Falconer AD, Kinnear RC, et al. HIV prevalence at reception into Australian prisons, 1991-1997. Med J Aust 1999; 171(1): 18-21.
  39. Edwards A, Curtis S, Sherrard J. Survey of risk behaviour and HIV prevalence in an English prison. Int J STD AIDS 1999; 10(7): 464-6.
  40. Long J, Allwright S, Barry J, Reynolds SR, Thornton L, Bradley F, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: A national cross sectional survey. BMJ 2001; 323(7323): 1209-13.
  41. Gaiter J, Jürgens R, Mayer K, Hollibaugh A. Harm reduction inside and out: controlling HIV in and out of correctional institutions. AIDS Read 2000; 10(1): 45.
  42. Rotily M, Weilandt C, Bird SM, Kall K, Van Haastrecht HJ, Iandolo E, et al. Surveillance of HIV infection and related risk behaviour in European prisons. A multicentre pilot study. Eur J Public Health 2001; 11(3): 243-50.
  43. Sosa-Estani S, Rossi D, Weissenbacher M. Epidemiology of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome in injection drug users in Argentina: High seroprevalence of HIV infection. Clin Infect Dis 2003; 37(Suppl 5): S338-S342.
  44. March JC, Oviedo-Joekes E, Romero M. Factors associated with reported hepatitis C and HIV among injecting drug users in ten European cities. Enferm Infecc Microbiol Clin 2007; 25(2): 91-7.
  45. Iran Drug Control Headquarters. Iran Drug Control Headquarters [Online]. [cited 2010]; Available from: URL: http:// html/ index.php? Module=htmlpages&func=displ ay&PID=37
  46. Centre for Communicable Diseases Management. HIV infection and AIDS statistics in Iran. Tehran, Iran: Ministry of Health and Medical Education; 2013.
  47. Day C, Nassirimanesh B, Shakeshaft A, Dolan K. Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduct J 2006; 3: 2.
  48. Nasirian M, Doroudi F, Gooya MM, Sedaghat A, Haghdoost AA. Modeling of human immunodeficiency virus modes of transmission in Iran. J Res Health Sci 2012; 12(2): 81-7.
  49. Wodak A, Cooney A. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDs among injecting drug users. Geneva, Switzerland: World Health Organization; 2004.
  50. Farnia M, Shahbazi M, Moradi G, Alizadeh S, Ebrahi B, Kandi Kalle M. Evaluation of Harm reduction Programs in prisons from the attitude and viewpoint of Iranian prison staff. J Sch Public Health Inst Public Health Res 2013; 11(1): 29-44. [In Persian].
  51. Keshtkaran A, Mirahmadizadeh A, Heidari A, Javanbakht M. Cost-effectiveness of Methadone Maintenance Treatment in Prevention of HIV Among Drug Users in Shiraz, South of Iran. Iran Red Crescent Med J 2014; 16(1): e7801. [In Persian].
  52. World Health Organization. Condoms for HIV prevention [Online]. [cited 2009]; Available from: URL:
  53. Sieck CJ, Dembe AE. Results of a pilot study of pre-release STD testing and inmates' risk behaviors in an Ohio prison. J Urban Health 2011; 88(4): 690-9.
  54. Mansorian M, Solhi M, Dehdari T, Taghdisi MH, Zamani Alvicheh F, Qorbani M, et al. The cause of utilization of shared needle among injecting drug users of Ahwaz city: A qualitative study. Razi J Med Sci 2012; 19(101): 31-9. [In Persian].
  55. Auerbach JD, Coates TJ. HIV prevention research: Accomplishments and challenges for the third decade of AIDS. Am J Public Health 2000; 90(7): 1029-32.
  56. Haghdoost A, Pourkhandani A, Motaghipisheh S, Farhoudi B, Fahimifar N, Sadeghirad B. Knowledge and Attitude concerning HIV/AIDS among Iranian Population: A Systematic Review and Meta- Analysis. Iranian Journal of Epidemiology 2011; 6(4): 8-20. [In Persian].